NLS Pharmaceutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-03-31 |
|---|---|---|
Gross Profit | -5 | -5 |
EBITDA | -1,943 | -4,408 |
EBIT | -1,948 | -4,408 |
Net Income | -2,035 | -4 |
Free Cash Flow | -1,530 | -2 |
Cash | 552 | 897 |
Basic Shares | 41,945 | 32,428 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -11 | -11 | -10 | |
EBITDA | -11,795 | -15,470 | -11,850 | |
EBIT | -3,636 | -11,807 | -15,482 | -11,860 |
Net Income | -1,980 | -12,172 | -16,495 | -11,946 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -4,271 | -9,684 | -13,879 | -14,975 |
Cash | 1,665 | 897 | 8,948 | 5,431 |
Basic Shares | 3,159 | 38,176 | 19,682 | 14,748 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-03-31 | -$0.99 |
2024-09-30 | -$1.94 |
2023-03-31 | -$0.33 |
2022-09-30 | -$0.54 |
